Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC
ACTIVE_NOT_RECRUITING
Status
Conditions
- Non Small Cell Lung Cancer
- Advanced Solid Tumor
- Metastatic Melanoma
- Metastatic Head and Neck Carcinoma
- Metastatic Renal Cell Carcinoma
- Metastatic Colorectal Cancer
- Sarcomas
- Metastatic Prostate Cancer
- Ovarian Cancer
- Small Cell Lung Cancer
- Metastatic Breast Cancer
- Pancreas Cancer
- Gastric Cancer
- Esophageal Cancer
- Gastroesophageal Junction Adenocarcinoma
- Cervical Cancer
- Adenoid Cystic Carcinoma
- Salivary Gland Cancer
- Urothelial Carcinoma
Interventions
- DRUG: ONC-392
- DRUG: Pembrolizumab
- DRUG: Docetaxel
Sponsor
OncoC4, Inc.
Collaborators